Intended for healthcare professionals


Calcium channel blockers and cancer. . . and other stories

BMJ 2018; 361 doi: (Published 14 June 2018) Cite this as: BMJ 2018;361:k2529

No increased mortality with CCBs

There has been some anxiety that calcium channel blockers might encourage growth of malignant cells by reducing intracellular calcium concentrations and inhibiting apoptotic gene expression. However, the findings of a record linkage study that tracked more than 20 000 breast cancer patients are reassuring. After adjustment for demographics, comorbidities, and the use of other sorts of medication, mortality from breast cancer was no higher in women who had taken calcium channel blockers than in women who had never used them. (Epidemiology doi:10.1097/EDE.0000000000000814)

Fit or faint?

It can be hard to decide whether a patient who …

View Full Text

Log in

Log in through your institution


* For online subscription